Generate Biomedicines, Inc. Common Stock (GENB) — Financial Flexibility Index
Generate Biomedicines, Inc. Common Stock (GENB) has a Financial Flexibility Index of -0.54x as of June 2026. Free cash flow of $-57.01 Million (operating CF $-57.94 Million minus capex $933.00K) represents -1% of total liabilities ($105.64 Million). Check Generate Biomedicines, Inc. Common Stock tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Generate Biomedicines, Inc. Common Stock Financial Flexibility Index (2024–2025)
Historical Financial Flexibility Index trend for Generate Biomedicines, Inc. Common Stock across 2 annual periods. For the full cash flow conversion analysis, see GENB cash flow conversion.
Annual Financial Flexibility Index for Generate Biomedicines, Inc. Common Stock (2024–2025)
Year-by-year free cash flow to debt coverage for Generate Biomedicines, Inc. Common Stock. Explore Generate Biomedicines, Inc. Common Stock (GENB) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.21x | $-197.10 Million | $-200.62 Million | $953.38 Million | ▼ -72.4% |
| 2024 | -0.12x | $-114.30 Million | $-117.75 Million | $953.35 Million | — |